Dr. François-Xavier Mahon - CML - CHRONIC MYELOID LEUKEMIA
Professeur d’Université Praticien hospitalier
Hématologie CHU Bordeaux
Université Bordeaux, France
Hématologie CHU Bordeaux
Université Bordeaux, France
VIDEOS
EURO-SKI trial: cessation of TKI treatment in CML patients with deep molecular response
December 14, 2016, VJHemOnc – Video Journal of Hematological Oncology
Francois-Xavier Mahon, et al.:
December 3, 2016, oncoletter
TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial
December 3, 2016, ecancer
Presentations - STIM STop IMatinib - Update (FX Mahon)
December 20, 2011, www.cmladvocates.net
EURO-SKI trial: cessation of TKI treatment in CML patients with deep molecular response
December 14, 2016, VJHemOnc – Video Journal of Hematological Oncology
Francois-Xavier Mahon, et al.:
December 3, 2016, oncoletter
TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial
December 3, 2016, ecancer
Presentations - STIM STop IMatinib - Update (FX Mahon)
December 20, 2011, www.cmladvocates.net
ARTICLES
The 2019 Goldman Prize is awarded to Professor François-Xavier Mahon
September 2019, iCMLf
At 2 Years, No CML Found in Half of Patients Who Stopped TKI Therapy
December 5, 2016, Cancer Network
TKI Cessation Strategies Emerging for CML
December 4, 2016. OncLive
Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
September 2016, Cancer Medicine
Discontinuation of imatinib may be possible in chronic myelogenous leukemia
March 3, 2011,Cancer Journal for Clinicians
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
October 2010, The Lancet Oncology
Some leukemia patients may be able to safely stop treatment
October 2010, PhysOrg.com
ASH 2008: Imatinib Can Be Discontinued in Some Patients With CML
December 8, 2008, Medscape
Leucémie myéloïde chronique
Juillet 2008, John Libbey Eurotext
The 2019 Goldman Prize is awarded to Professor François-Xavier Mahon
September 2019, iCMLf
At 2 Years, No CML Found in Half of Patients Who Stopped TKI Therapy
December 5, 2016, Cancer Network
TKI Cessation Strategies Emerging for CML
December 4, 2016. OncLive
Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
September 2016, Cancer Medicine
Discontinuation of imatinib may be possible in chronic myelogenous leukemia
March 3, 2011,Cancer Journal for Clinicians
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
October 2010, The Lancet Oncology
Some leukemia patients may be able to safely stop treatment
October 2010, PhysOrg.com
ASH 2008: Imatinib Can Be Discontinued in Some Patients With CML
December 8, 2008, Medscape
Leucémie myéloïde chronique
Juillet 2008, John Libbey Eurotext
See also Treatment free remission (TFR)
Voir les dernières nouvelles sur la leucémie myéloïde chronique
Voir CML experts in France
Voir les dernières nouvelles sur la leucémie myéloïde chronique
Voir CML experts in France